A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture
Phase of Trial: Phase II
Latest Information Update: 08 Jul 2019
Price : $35 *
At a glance
- Drugs Bimagrumab (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Novartis
- 06 Dec 2018 Status changed from active, no longer recruiting to completed.
- 04 Oct 2018 Planned End Date changed from 30 Oct 2018 to 25 Oct 2018.
- 11 Jul 2018 Planned primary completion date changed from 15 May 2018 to 15 Aug 2018.